Double-blind, randomized, double-dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain

Pérola Grinberg Plapler, Morton Aaron Scheinberg, Christina da Cunha Ecclissato, Monalisa Fernanda Bocchi de Oliveira, Roberto Bleuel Amazonas, Pérola Grinberg Plapler, Morton Aaron Scheinberg, Christina da Cunha Ecclissato, Monalisa Fernanda Bocchi de Oliveira, Roberto Bleuel Amazonas

Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common type of medication used in the treatment of acute pain. Ketorolac trometamol (KT) is a nonnarcotic, peripherally acting nonsteroidal anti-inflammatory drug with analgesic effects comparable to certain opioids.

Objective: The aim of this study was to compare the efficacy of KT and naproxen (NA) in the treatment of acute low back pain (LBP) of moderate-to-severe intensity.

Patients and methods: In this 10-day, Phase III, randomized, double-blind, double-dummy, noninferiority trial, participants with acute LBP of moderate-to-severe intensity as determined through a visual analog scale (VAS) were randomly assigned in a 1:1 ratio to receive sublingual KT 10 mg three times daily or oral NA 250 mg three times daily. From the second to the fifth day of treatment, if patient had VAS >40 mm, increased dosage to four times per day was allowed. The primary end point was the reduction in LBP as measured by VAS. We also performed a post hoc superiority analysis.

Results: KT was not inferior to NA for the reduction in LBP over 5 days of use as measured by VAS scores (P=0.608 for equality of variance; P=0.321 for equality of means) and by the Roland-Morris Disability Questionnaire (P=0.180 for equality of variance test; P=0.446 for equality of means) using 95% confidence intervals. The percentage of participants with improved pain relief 60 minutes after receiving the first dose was higher in the KT group (24.2%) than in the NA group (6.5%; P=0.049). The most common adverse effects were heartburn, nausea, and vomiting.

Conclusion: KT is not inferior in efficacy and delivers faster pain relief than NA.

Keywords: acute low back pain; ketorolac trometamol; naproxen; nonsteroidal anti-inflammatory drugs.

Figures

Figure 1
Figure 1
Enrollment and randomization flowchart. Note: Adverse effect: cholecystitis, improbably associated with the test drug. Abbreviations: KT, ketorolac trometamol; NA, naproxen.
Figure 2
Figure 2
Pain relief rate 1 hour after medication. Abbreviation: NA, naproxen.

References

    1. Wynne-Jones G, Cowen J, Jordan JL, et al. Absence from work and return to work in people with back pain: a systematic review and meta-analysis. Occup Environ Med. 2014;71(6):448–456.
    1. Hills EC [webpage on the Internet] Mechanical Low Back Pain. 2014. [Accessed May 13, 2016]. [updated Aug 4, 2014]. Available from: .
    1. Ijzelenberg W, Burdorf A. Risk factors for musculoskeletal symptoms and ensuing health care use and sick leave. Spine. 2005;30(13):1550–1556.
    1. Vadivelu N, Mitra S, Narayan D. Recent advances in postoperative pain management. Yale J Biol Med. 2010;83(1):11–25.
    1. Lötsch J, Geisslinger G. Current evidence for genetic modulation of the response to analgesics. Pain. 2006;121:1–5.
    1. Eksterowicz N, Quinlan-Cowell A, Vanderveer B, Menez J. Acute Pain Management. Core Curriculum for Pain Management Nursing. 2nd ed. Dubuque, IA: Kendall Hunt Professional; 2010. p. 343.
    1. Ghafoor V, Marie BS. Overview of pharmacology. In: Marie BJ, editor. Core Curriculum for Pain Management Nursing. 2nd ed. Dubuque, IA: Kendall Hunt Professional; 2010. pp. 236–242.
    1. Truven Health Analytics [webpage on the Internet] Ketorolac tromethamine DRUGDEXSystem (Micromedex 20) Greenwood Village, CO: Truven Health Analytics; 2016. [Accessed April 04, 2016]. pp. c2012–c2016. Available from: .
    1. Patrocinio LG, Rangel MO, Miziara GSM, Rodrigues AM, Patrocinio JA, Patrocinio TG. A comparative study between Ketorolac and Ketoprofen in postoperative pain after uvulopalatopharyngoplasty. Rev Bras Otorrinolaringol. 2007;73(3):339–342.
    1. Olmedo MV, Gálvez R, Vallecillo M. Double-blind parallel comparison of multiple doses of ketorolac, ketoprofen and placebo administered orally to patients with postoperative dental pain. Pain. 2001;90(1–2):135–141.
    1. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2008.
    1. FDA . Guidance for Industry Non-Inferiority Clinical Trial. Rockville, MD: Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2010.
    1. Paula GA. Modelos de regressão com apoio computacional. [Regression models with computer support] IME-USP; São Paulo, Brazil: 2004. Portuguese.
    1. Hoffmann-La Roche . Toradol® (ketorolac tromethamine): 10 mg tablets; Toradol® IM (ketorolac tromethamine injection) 10 mg/mL or 30 mg/mL intramuscular injection [product monograph] Mississauga (ON): Hoffmann-La Roche; 2003.
    1. Alexander R, El-Moalem HE, Gan TJ. Comparison of the morphine-sparing effects of diclofenac sodium and ketorolac tromethamine after major orthopedic surgery. J Clin Anesth. 2002;14(3):187–192.
    1. Chen JY, Wu GJ, Mok MS, et al. Effect of adding ketorolac to intravenous morphine patient-controlled analgesia on bowel function in colorectal surgery participants – a prospective, randomized, double-blind study. Acta Anaesthesiol Scand. 2005;49(4):546–551.
    1. Rainer TH, Jacobs P, Ng YC, et al. Cost effectiveness analysis of intravenous ketorolac and morphine for treating pain after limb injury: double blind randomized controlled trial. BMJ. 2000;321(7271):1247–1251.
    1. Veenema KR, Leahey N, Schneider S. Ketorolac versus meperidine: ED treatment of severe musculoskeletal low back pain. Am J Emerg Med. 2000;18(4):404–407.
    1. Innes GD, Croskerry P, Worthington J, Beveridge R, Jones D. Ketorolac versus acetaminophen-codeine in the emergency department treatment of acute low back pain. J Emerg Med. 1998;16(4):549–556.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅